Jens Holstein Biography and Net Worth

Director of Veracyte

Jens Holstein has 25 years of financial and management expertise, spanning an array of global life science businesses. In 2011, Mr. Holstein was appointed Chief Financial Officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany. Before joining MorphoSys, Mr. Holstein worked at the pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as Regional Chief Financial Officer for the Europe/Middle East Region and as Managing Director of Fresenius Kabi Deutschland GmbH. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group including Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects and Service business unit of Fresenius, and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry. He holds a Diploma in Business Administration from the University of Münster (Germany).

What is Jens Holstein's net worth?: The estimated net worth of Jens Holstein is at least $839,685.36 as of August 7th, 2024. Mr. Holstein owns 27,878 shares of Veracyte stock worth more than $839,685 as of March 30th. This net worth evaluation does not reflect any other assets that Mr. Holstein may own. Learn More about Jens Holstein's net worth.
How do I contact Jens Holstein?: The corporate mailing address for Mr. Holstein and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at keith@veracyte.com. Learn More on Jens Holstein's contact information.
Has Jens Holstein been buying or selling shares of Veracyte?: Jens Holstein has not been actively trading shares of Veracyte over the course of the past ninety days. Most recently, Jens Holstein sold 5,000 shares of the business's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $29.00, for a transaction totalling $145,000.00. Following the completion of the sale, the director now directly owns 27,878 shares of the company's stock, valued at $808,462. Learn More on Jens Holstein's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 17 times. They sold a total of 88,392 shares worth more than $2,810,829.26. The most recent insider tranaction occured on February, 3rd when CFO Rebecca Chambers sold 527 shares worth more than $23,108.95. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 2/3/2025.

Jens Holstein Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/7/2024	Sell	5,000	$29.00	$145,000.00	27,878
6/14/2022	Sell	8,720	$16.27	$141,874.40	2,000
6/3/2021	Buy	2,000	$35.19	$70,380.00	2,000

Jens Holstein Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Today's Range

Now: $30.12

$29.65

$31.07

50 Day Range

MA: $37.57

$30.12

$46.14

2 Week Range

Now: $30.12

$18.61

$47.32

Volume

710,014 shs

Average Volume

835,914 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8